Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Once-daily Trelegy Ellipta gains expanded COPD indication in Europe
Once-daily Trelegy Ellipta now available for COPD patients requiring a step up from dual bronchodilation
-
Statement: GSK supports GOLD committee’s efforts to further personalise COPD management
Welcoming the updated Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy.
-
ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir at 48 weeks in heavily treatment-experienced patients with HIV
BRIGHTE study highlights ViiV Healthcare’s commitment to developing innovative medicines for all people living with HIV
-
GSK delivers Q3 sales of £8.1 billion, +3% AER, +6% CER
Total EPS 28.8p, +16% AER, +23% CER; Adjusted EPS 35.5p, +10% AER, + 14% CER
-
ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen
FLAIR study meets primary endpoint
-
ViiV Healthcare presents three-year data for investigational long-acting injectable, two-drug HIV regimen
LATTE-2 study shows high rates of virologic response & long-term durability with long-acting, injectable, two-drug regimen over 160 weeks.
-
GSK announces positive phase 3 results for daprodustat in patients with anaemia associated with chronic kidney disease
Second of three pivotal studies intended to support regulatory filing in Japan in 2019
-
GSK presents new efficacy and safety data of an anti GM-CSF antibody in patients with rheumatoid arthritis
Marked patient benefit observed in phase II study supports further clinical development of GSK3196165 for RA.
-
ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
Priority review voucher used with NDA submission with anticipated target action date of six months.
-
GSK updates policy for working with healthcare professionals
We are updating our policy on working with healthcare professionals (HCPs).
-
Positive results from Harmony Outcomes study of albiglutide published in The Lancet
GSK & DCRI announced publication of positive results from the Harmony Outcomes study which assessed CV safety and efficacy of albiglutide.
-
GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study
Positive impact of innovative vaccine technology in clinical trial conducted in tuberculosis endemic regions
-
GSK and Tres Cantos Open Lab Foundation announce additional £5m funding for open innovation research in diseases impacting the developing world
Additional £5m in GSK funding to support the Foundation’s research and development programmes in diseases of the developing world.
-
Trelegy Ellipta receives positive CHMP opinion supporting expanded COPD indication in Europe
European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion supporting use of Trelegy Ellipta
-
Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria
Approval marks a major step in global eradication efforts and will support registrations in malaria-endemic countries
-
ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
ViiV announced submission of MAA to EMA for a single-tablet, two-drug regimen of DTG and 3TC for the treatment of HIV-1 infection.
-
GSK data presented at ERS further supports its industry-leading respiratory medicines portfolio
GSK will profile the growing evidence base that supports its broad respiratory medicines portfolio at ERS congress in Paris, France, 09/18.
-
GSK announces results of indirect treatment comparisons of Nucala to benralizumab and reslizumab for severe eosinophilic asthma
Nucala demonstrated greater reduction in exacerbations and improved asthma control.
-
GSK receives complete response letter from US FDA for use of mepolizumab in COPD patients
GlaxoSmithKline plc(LSE/NYSE: GSK) today received a complete response letter (CRL) from the US FDA regarding its application for mepolizumab
-
European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma
First anti-IL-5 biologic treatment for paediatric patients with severe eosinophilic asthma in Europe